The time has come: sparing injectables in paediatric MDR-TB.
作者信息
Weld Ethel D, Garcia-Prats Anthony J, Furin Jennifer J, Bailey Theodore C, Hesseling Anneke C, Dooley Kelly E
机构信息
The Johns Hopkins University School of Medicine, Department of Medicine, Divisions of Clinical Pharmacology & Infectious Disease, Baltimore, MD, USA.
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
出版信息
Lancet Respir Med. 2017 Mar 15. doi: 10.1016/S2213-2600(17)30078-4.
Abstract
摘要
相似文献
1
The time has come: sparing injectables in paediatric MDR-TB.
Lancet Respir Med. 2017 Mar 15. doi: 10.1016/S2213-2600(17)30078-4.
2
The safety and tolerability of the second-line injectable antituberculosis drugs in children.
Expert Opin Drug Saf. 2016 Nov;15(11):1491-1500. doi: 10.1080/14740338.2016.1223623. Epub 2016 Aug 22.
3
Community engagement for paediatric MDR-TB clinical trials: principles to support ethical trial implementation.
Int J Tuberc Lung Dis. 2018 May 1;22(5):40-45. doi: 10.5588/ijtld.17.0356.
4
Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
BMC Pharmacol Toxicol. 2019 May 23;20(1):31. doi: 10.1186/s40360-019-0313-y.
5
The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide.
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S46-S47. doi: 10.1016/j.ijmyco.2016.10.015. Epub 2016 Oct 27.
6
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
7
Pediatric multi-drug-resistant tuberculosis in Germany - diagnostic and therapeutic challenges of an "orphan disease".
Eur J Pediatr. 2023 Nov;182(11):5167-5179. doi: 10.1007/s00431-023-05167-x. Epub 2023 Sep 14.
8
Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.
Euro Surveill. 2017 Nov;22(47). doi: 10.2807/1560-7917.ES.2017.22.47.17-00103.
9
Paediatric Multidrug-Resistant Tuberculosis with HIV Coinfection: A Case Report.
Case Rep Med. 2013;2013:756152. doi: 10.1155/2013/756152. Epub 2013 Jan 23.
10
Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.
Drug Resist Updat. 2013 Dec;16(6):108-15. doi: 10.1016/j.drup.2014.02.003. Epub 2014 Feb 28.
引用本文的文献
1
Management of drug-resistant tuberculosis.
Lancet. 2019 Sep 14;394(10202):953-966. doi: 10.1016/S0140-6736(19)31882-3.
2
Management of patients with multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.
本文引用的文献
1
Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.
Antimicrob Agents Chemother. 2015 Oct;59(10):6337-43. doi: 10.1128/AAC.01050-15. Epub 2015 Jul 27.
2
Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study.
BMC Infect Dis. 2014 Aug 1;14:426. doi: 10.1186/1471-2334-14-426.
3
High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.
Thorax. 2014 May;69(5):458-64. doi: 10.1136/thoraxjnl-2013-203900. Epub 2013 Sep 24.
4
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.
Eur Respir J. 2013 Jul;42(1):156-68. doi: 10.1183/09031936.00134712. Epub 2012 Oct 25.
5
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
PLoS Med. 2012;9(8):e1001300. doi: 10.1371/journal.pmed.1001300. Epub 2012 Aug 28.
6
Delamanid for multidrug-resistant pulmonary tuberculosis.
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
7
Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection.
Int J Otolaryngol. 2011;2011:937861. doi: 10.1155/2011/937861. Epub 2011 Oct 25.
8
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.
Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54. doi: 10.5588/ijtld.10.0616.
9
Health inequities and social justice. The moral foundations of public health.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Feb;51(2):151-7. doi: 10.1007/s00103-008-0443-7.
10
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
PLoS Med. 2006 Nov;3(11):e466. doi: 10.1371/journal.pmed.0030466.
Zotero 插件